PRAME red
Use
Preferentially expressed antigen in melanoma (PRAME) is a melanoma-associated antigen that acts as a repressor of the retinoic acid receptor signaling pathway. PRAME stains many melanoma subtypes diffusely positive as well as other malignant tumors such as certain sarcomas, carcinomas, and hematolymphoid neoplasms. PRAME is basally expressed in benign testis, ovary, placenta, adrenals, and endometrium tissues. This IHC assay is performed with RED chromogen.
Special Instructions
Not provided.
Limitations
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Methodology
Immunoassay (IHC)
Biomarkers
PRAME
Protein
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (Fixed (Non-FFPE))
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Fixative should be at a 20:1 fixative to tissue ratio, 10% neutral buffered formalin (NBF) for 6-72 hours (48-72 hours PREFERRED)
Storage Instructions
15°C to 25°C
Causes for Rejection
Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | ≤ 72 Hours |